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Summary 
This study explored the effect of MS-275, a novel histone deacetylase inhibitor 
(HDACI), against a variety of human leukemia cells with defined genetic alterations. 
MS-275 profoundly induced growth arrest of acute myelogenous leukemia (AML) 
MOLM13 and biphenotypic leukemia MV4-11 cells, which possess internal tandem 
duplication mutation in the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD), with 
IC50s less than 1 μM, as measured by 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide assay on day two of culture. Exposure of these cells to 
MS-275 decreased levels of total, as well as, phosphorylated forms of FLT3, resulting in 
inactivation of its downstream signal pathways, including Akt, ERK, and STAT5. 
Further studies found that MS-275 induced acetylation of heat shock protein 90 
(HSP90) in conjunction with ubiquitination of FLT3, leading to degradation of FLT3 
proteins in these cells. This was blunted by treatment with the proteasome inhibitor 
bortezomib, confirming that FLT was degraded via ubiquitin/proteasome pathway. 
Moreover, we found that further inhibition of MEK/ERK signaling potentiated the 
action of MS-275 in leukemia cells. Taken together, MS-275 may be useful for 
treatment of individuals with leukemia possessing activating mutation of FLT3 gene.  
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Introduction 
The class III receptor tyrosine kinases (RTKs), including fms-like tyrosine kinase 3 
(FLT3), c-KIT, and platelet-derived growth factor receptor (PDGFR) are implicated in 
the pathophysiology of several cancers as well as leukemias. These RTKs all share the 
same topology, consisting of five extracellular immunoglobulin-like domains, a 
juxtamembrane (JM) domain, a kinase domain interrupted by a kinase insertion domain, 
and an intracellular C-terminal domain [1]. Ligand binding to RTKs results in the 
activation of downstream effectors, including protein kinase B/Akt, signal transducers 
and activators of transcription (STATs) and extracellular signal-regulated kinases 
(ERKs) 1/2, leading to cell proliferation, differentiation and/or survival [2,3]. Recent 
studies have revealed that activating mutations of RTKs frequently occur in acute 
myelogenous leukemia (AML) patients. For example, internal tandem duplications 
(ITDs) of the JM domain of FLT3 (FLT3-ITD) are present in 20–30% of de novo AML 
cases [4]; and approximately 7% of AML patients possess the D835 mutation, a point 
mutation in the activation loop of the second kinase domain of FLT3 [4]. These 
mutations result in constitutively activated FLT3 and its downstream signal pathways, 
and are associated with elevated blast counts, increased relapse rates and poor overall 
survival in AML [5-8]. Mutations of c-KIT and PDGFR are also associated with subsets 
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of AML [9-12]. Therefore, RTK is a therapeutic target and inhibition of activity of RTK 
may provide a new approach in the treatment of AML patients carrying these mutations. 
Heat shock protein 90 (HSP90) is a member of the HSP family and consist of α 
and β subunits [13]. HSP90 is ubiquitous and functions as chaperone in cytosol, where 
they stabilize select proteins including hormone receptors, cyclin dependent kinase 4, as 
well as, RTKs [14]. In addition, HSP90 chaperone complexes prevent degradation of 
mutated proteins including FLT3-ITD, sustaining the function of these proteins [14]. 
Recent studies showed that inhibition of HSP90 by 17-allylamino-demethoxy 
geldanamycin (17-AAG) provoked degradation of FLT3-ITD via ubiquitin/proteasome 
pathway and inhibited the proliferation of leukemia cells with FLT3-ITD [15,16]. 
Deacetylation of HSP90 at K294 mediated by HDAC6 is critical for chaperon 
function; when HDAC6 was genetically knocked down, HSP90 k294 was acetylated 
and ATP binding to HSP90 was blocked, resulted in impairment of its chaperon function 
[17]. The hydroxamic acid analogue pan-HDACIs, LAQ824 and LBH589 preferentially 
inhibit HDAC6 [18]. Both induced acetylation and inhibition of HSP90, resulting in 
degradation of BCR/ABL oncoprotein and Akt in chronic myeloid leukemia K562 cells 
[18].         
MS-275, a novel and orally available synthetic benzamide HDACI, perferentially 
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inhibits HDAC1, and does not possess activity against HDAC6 [19,20]. The in vitro 
enzymatic assay showed that IC50 of MS-275 against HDAC1 was 2.2 μM. On the 
other hand, even 100 μM of MS-275 was not able to inhibit the enzymatic activity of 
HDAC6 [21]. MS-275 induced differentiation and/or apoptosis of human leukemia 
U937, HL-60, K562 and Jurkat cells [21,22]. This study examined the effects of 
MS-275 on human leukemia cells expressing FLT3-ITD. Also, we investigated the drug 
interaction of MS-275 and the novel MEK/ERK inhibitor AZD6244 (ARRY-142886) 
[23] with these cells. 
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Materials and Methods 
Cells. Characteristics of the cell lines utilized in this study have been described [24]. 
Leukemia cells from patients were freshly isolated with informed consent and 
institutional review board approval. The informed consent was provided according to 
the Declaration of Helsinki. 
Reagents. MS-275 was provided by Schering AG (Berlin, Germany), and dissolved in 
100 % dimethyl sulfoxide (DMSO; Burdick & Jackson, Muskegon, MI) to a stock 
concentration of 10-2 M and stored at -80°C. PS-341 was provided by Millennium 
Pharmaceuticals (Cambridge, MA) and dissolved in PBS to a stock concentration of 
10-2 M and stored at -80°C.  
Growth inhibition assays. To assess the anti-proliferative effect of MS-275 against 
various types of leukemia cells, either 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or 
3H-thymidine uptake was utilized for leukemia cell lines or freshly isolated leukemia 
cells from patients, respectively, as previously described [24]. All experiments were 
performed in triplicate and repeated at least three times.  
FLT3 genotyping. FLT3-ITD mutation was examined as previously described [24]. 
Cell cycle analysis by flow cytometry. Cell cycle analysis was performed as previously 
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described [24].  
Apoptosis assays. The ability of MS-275 to induce apoptosis of leukemia cells was 
measured using the annexin V-FITC apoptosis detection kit (Pharmingen, Inc., San 
Diego, CA), according to the manufacturer’s instructions. 
Flow cytometry. The effect of MS-275 on FLT3 and its downstream signals was 
assessed by flow cytometry. Anti-FLT3/CD135 (Abcam, Cambridge, UK, ab23895), 
-p-FLT3 (Tyr591, Cell Signaling Technology, Beverly, MA, #3461), -ERK (Cell 
Signaling Technology, #4374), -p-ERK (Cell Signaling Technology, #9102), -Akt (Cell 
Signaling Technology, #9272), -p-Akt (Ser473, Cell Signaling Technology, #9271), 
-Stat5 (C-17; Santa Cruz, Santa Cruz, CA, sc-835), -p-Stat5 (Tyr694, Cell Signaling 
Technology, #9351), cleaved caspase 3 (Cell Signaling Technology, #9661) and 9 (Cell 
Signaling Technology, #9501), cleaved PARP (Cell Signaling Technology, #9541) 
antibodies were used.  
The multiparameter flow cytometric analysis was performed to access the effect of 
MS-275 on acetylation of HSP90 and ubiquitination of FLT3 in leukemia cells. To 
quantify acetylated HSP90 positive population, cells were simultaneously stained with 
anti-HSP90α/β (F-8; Santa Cruz, sc-13119) and anti-acetylated lysine antibodies (R&D 
systems), followed by staining with FITC-conjugated goat anti-rabbit (Caltag 
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Laboratories, Burlingame, CA) and PE-conjugated goat anti-mouse secondary 
antibodies (Caltag Laboratories, Burlingame, CA). The ubiquitinated FLT3 expressing 
cells were quantified using anti-human ubiquitin (R&D systems, CPJ02) and 
anti-Flt3/CD135 (Abcam) antibodies. Data analysis was performed with the Cell Quest 
software (Becton Dickinson, San Jose, CA). 
Immunoprecipitation of HSP90 or FLT3. To further confirm the effects of MS-275 on 
acetylation of HSP90 and ubiquitination of FLT3 in leukemia cells, 
immunoprecipitation followed by Western blot analysis was employed. Lysates from 
MV4-11 and MOLM13 cells were prepared and immunoprecipitated with the indicated 
antibody and protein G Sepharose (Pierce, Rockford, IL), as previously described [23]. 
The precipitated samples were subjected to Western blot analysis, as previously 
described [24]. The membrane was sequentially probed with the indicated antibodies.  
Western blot analysis. Western blot analysis was done as described previously [24]. 
Anti-Bcl-2 (Santa Cruz), -Bcl-xL (Cell signaling), -Mcl-1 (Santa Cruz), and -α-tubulin 
(Santa Cruz) antibodies were used. 
Data analysis. The combination index (CI) for growth inhibition elicited by MS-275 
and AZD6244 in leukemia cells was calculated using the median effect method of Chou 
and Talalay [25] (Calcusyn Software available from Biosoft, Cambridge, United 
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Kingdom). CI values <1 indicate synergy, a CI = 1 indicates an additive effect, and a CI 
>1 indicates antagonism between the two agents. 
Statistical analysis. Statistical analyses were carried out using the SPSS software 
(SPSS Japan, Tokyo, Japan) and the results were considered to be significant when the 
P-value was < 0.05, and highly significant, when the P-value was < 0.01. To assess the 
difference between two groups under multiple conditions, one-way ANOVA followed 
by Boneferroni’s multiple comparison tests were performed by using PRISM statistical 
analysis software (GraphPad Software Inc, San Diego, CA, USA). 
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Results 
MS-275 induces growth arrest of leukemia cells with FLT3-ITD. A variety of types 
of leukemia cells were exposed to various concentrations of MS-275 (0.1-5 μM) and 
their viability was determined by MTT assay on day 2 of culture. Results were graphed 
(data not shown), and the effective dose of MS-275 that inhibited 50% growth (IC50s) of 
these cell lines was calculated (Table 1). IC50 of MS-275 for either MV4-11 or 
MOLM13 cells was 0.74 and 0.67 μM, respectively. MS-275 was also active against 
EOL-1 and Kasumi-1 cells which express an activating mutation of PDGFRα and c-KIT, 
respectively (Table 1). Moreover, MS-275 was able to inhibit the proliferation of 
freshly-isolated leukemia cells with FLT3-ITD (Table 2). 
Effect of MS-275 on the cell cycle of leukemia cells. To investigate the mechanisms 
by which MS-275 inhibited the growth of MOLM13 and MV4-11 leukemia cells, we 
explored the effect of MS-275 on cell cycle distribution of these cells by flow cytometry 
(Fig.1). MS-275 (0.5 or 1μM, 48 hrs) profoundly caused the accumulation of these cells 
in the pre-G1 phase of the cell cycle, a feature characteristic of apoptosis with a 
concomitant decrease in the proportion of cells in the S phase (Fig.1). For example, 69 ± 
4 % and 77 ± 5 % of either MOLM13 or MV4-11 cells accumulated in the pre-G1 phase 
of the cell cycle after exposure to MS-275 (1μM, 48 hrs) (Fig. 1A).    
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Effect of MS-275 on apoptosis of leukemia cells. Annexin V binds to cells that 
express phosphatidylserine on the outer layer of the cell membrane, a characteristic of 
cells entering apoptosis. Exposure of either MOLM13 or MV4-11 cells to MS-275 
(1μM) for 48 hrs markedly increased the proportion of cells positive for Annexin V 
(42 % of MOLM13, 60 % of MV4-11) (Fig. 1B).  
MS-275 decreases levels of Bcl-2 family members in leukemia cells. Bcl-xL plays a 
pivotal role in FLT3 kinase inhibitor-mediated apoptosis in FLT3-ITD expressing 
leukemia cells [26]. Exposure of MOLM13 and MV4-11 cells to MS-275 (0.5 or 1μM, 
48 hrs) lowered levels of Bcl-xL and Mcl-1, while levels of Bcl-2 did not change 
(Fig.1C). As levels of anti-apoptotic protein decreased, caspases 3 and 9 were activated, 
as indicated by the appearance of the cleaved forms of these proteins, leading to 
cleavage of PARP, a feature characteristic of apoptosis (Fig.1C).   
MS-275 inhibits FLT3 and its downstream signal pathways in MOLM13 and MV4 
-11 cells. Exposure of MOLM13 and MV4-11 cells to MS-275 (0.5-2 μM) for 24 hrs 
decreased the percent of the population expressing the phosphorylated form, as well as 
total amount of FLT3 in a dose-dependent manner (Figs. 2A,B). This occurred in 
parallel with downregulation of p-Akt, p-ERK, and p-STAT5, which are downstream of 
FLT3 (Figs. 2A,B).  
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MS-275 induces acetylation of HSP90 in leukemia cells. FLT3 is a client protein for 
the chaperone HSP90 [27], which raised the possibility that MS-275 could acetylate 
HSP90, resulting in impairment of its chaperone function and degradation of FLT3 via 
ubiquitin/proteasome pathway. To verify this hypothesis, we examined whether MS-275 
acetylated HSP90 in MV4-11 and MOLM13 cells by utilizing multiparameter flow 
cytometric analysis. Approximately 50 % of MOLM13 and MV4-11 cells expressed 
acetylated HSP90; exposure of these cells to MS-275 (1 μM, 24 hrs) increased the 
acetylated HSP90 expressing population to approximately 90 % (Fig. 3A). Acetylation 
of HSP90 is linked to the inactivation of its chaperone activity, leading to ubiquitination 
of the client proteins [14,15]. We next explored whether MS-275 induced ubiquitination 
of FLT3 in leukemia cells. As expected, exposure of MV4-11 and MOLM13 cells to 
MS-275 (1 μM, 24 hrs) markedly induced ubiquitination of FLT3 in these cells (Fig. 
3B). We further confirmed MS-275-induced acetylation of HSP90 in MV4-11 and 
MOLM13 cells by immunoprecipitation followed by Western blot analysis (Fig. 3C). In 
parallel with this, direct interaction between HSP90 and FLT3 was inhibited, resulting 
in ubiquitination of FLT3 in these cells (Fig 3D). Polyubiquitination of client proteins 
results in degradation by 26 S proteasome [28,29]. Pretreatment of MV4-11 and 
freshly-isolated leukemia cells (#1 and #2 in Table 2) with the proteasome inhibitor 
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PS-341 (1 nM, 1 hr) blunted MS-275-induced downregulation of FLT3 (Fig. 3E), 
confirming that the FLT3 protein was degraded via ubiquitin/proteasome pathway.  
AZD6244 enhanced the anti-proliferative effect of MS-275 in leukemia cells. As 
shown above, MS-275 potently inhibited phosphorylation of FLT3 in MOLM13 and 
MV4-11 cells, but blockade of one of the downstream signals, p-ERK, was only partial. 
We, therefore, examined the impact of inhibition of MEK/ERK signaling by AZD6244 
on the action of MS-275 in these cells. p-ERK was expressed in 96 % and 89 % of 
control MV4-11 or MOLM13 cells, respectively (Fig.4A); exposure of these cells to 
MS-275 (0.5 μM, 24 hrs) alone decreased the p-ERK-positive population to 
approximately 79 % (MV4-11) or 66 % (MOLM13) (Fig. 4A). AZD6244 potently 
inhibited phosphorylation of ERK with either 10 % or 18 % of MV4-11 and MOLM13 
cells having p-ERK positivity after exposure to AZD6244 (0.25 μM, 15 min) (Fig. 4A). 
When these cells were exposed to a combination of both of these compounds, p-ERK 
positive population decreased to 2 % in both cell lines (Fig. 4A). We next examined the 
effect of the combination of MS-275 and AZD6244 on proliferation of MV4-11 and 
MOLM13 cells. The cells were cultured in the presence of either MS-275 (0.1-1 μM) 
and/or AZD6244 (0.1–1 μM) for 48 hrs and proliferation was measured. As shown in 
Fig 4B, the CI value was <1, indicating a synergistic anti-proliferative effect when these 
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cells were treated with both compounds.  
Effect of MS-275 and AZD6244 on the cell cycle in leukemia cells. In addition, we 
studied the effect of concomitant addition of AZD6244 (0.25 μM) and MS-275 (0.25 or 
0.5 μM) on cell cycle distribution of MV4-11 and MOLM13 cells. Accumulation of 
cells in the sub-G1 phase fraction and decrease in the proportion of cells in the S phase 
of the cell cycle in both cell lines was significantly enhanced in the presence of both 
MS-275 and AZD6244 compared to either compound alone (p<0.01, Fig. 4C).  
Effect of MS-275 and AZD6244 on apoptosis in leukemia cells. In addition, the 
combination of MS-275 and AZD6244 synergistically enhanced apoptosis of leukemia 
cells (Fig. 4D). For example, addition of either MS-275 (0.5 μM, 48 hrs) or AZD6244 
(0.25 μM, 48 hrs) alone resulted in either 25 ± 5 or 14 ± 3 % of MV4-11 cells becoming 
annexin V positive, respectively. When these cells were exposed to a combination of 
both of these compounds, 38 ± 4 % of cells became annexin V positive (p<0.01, Fig. 
4D). 
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Discussion 
This study found that MS-275, a novel HDACI with selectivity against HDAC1, 
induced growth arrest and apoptosis of FLT3-ITD expressing MV4-11 and MOLM13 
leukemia cells (Fig 1, Table 1). MS-275 induced acetylation of HSP90 and 
ubiquitination of FLT3, which provoked degradation of FLT3 via the proteasome 
pathway (Fig 3). Previous studies showed that HDAC6 deacetylased HSP90, stabilized 
chaperone complexes, and prevented client proteins from proteasome-mediated 
degradation. This study suggested that HDAC1 was also involved in deacetylation and 
stabilization of chaperone proteins. 
MS-275 potently inhibited phosphorylation of FLT3, although blockade of 
p-ERK was partial. Inhibition of MEK/ERK signaling by AZD6244 synergistically 
enhanced MS-275-mediated growth arrest and apoptosis of MV4-11 and MOLM13 
cells (Fig 4). Recent studies performed by other investigators also found that inhibition 
of MEK/ERK signaling enhanced HDACI-induced growth arrest and apoptosis of both 
colon cancer H-29 and chronic myeloid leukemia K562 and LAMA 84 cells [30,31]. 
They showed that enhanced growth inhibition and apoptosis mediated by the 
combination of the MEK inhibitor and HDACI was associated with synergistic 
induction of reactive oxygen species, mitochondrial damage, and caspase activation 
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[29,30]. Similarly, we and others have shown that inhibition of MEK/ERK signaling 
potentiated the action of tyrosine kinase inhibitors, including imatinib, ZD6474, and 
dasatinib in human leukemia cells [32-34].  
In summary, MS-275 effectively induced growth arrest and apoptosis of leukemia 
cells possessing activating mutations of RTK; and these effects were potentiated by 
concomitant blockade of signaling by MEK/ERK. Inhibition of chaperone function of 
HSP90, at least in part, appeared to play an important role in MS-275-mediated growth 
arrest of leukemia cells. A recent phase 1 clinical trial with MS-275 has evaluated 
efficacy and safety of MS-275 in 38 individuals with relapsed or refractory AML [34]. 
MS-275 induced acetylation of histone H3/H4, expression of p21waf1 and activation of 
caspase 3 in bone marrow mononuclear cells, although no responses were observed by 
classical criteria [35]. Future clinical studies should assess the effect of MS-275 in 
individuals with AML possessing FLT3-ITD. Concomitant administration of MS-275 
and AZD6244 may represent a promising treatment strategy for individuals with AML. 
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Figure legends 
Fig. 1. Anti-proliferative effects of MS-275 against leukemia cells. (Panel A), Cell 
cycle analysis. MOLM13 and MV4-11 cells were cultured with MS-275 (0.1-1μM). 
After 48 hrs, cell cycle distribution of these cells was analyzed. Statistical significance 
was determined by paired t-test. Results represent the mean ± SD of 3 experiments 
performed in duplicate; *, p< 0.01, with respect to control. (Panel B), Annexin V 
staining. MOLM13 and MV4-11 cells were cultured with MS-275 (0.1-1μM). After 48 
hrs, cells were stained with annexin-V/ propidium iodide, and analyzed by flow 
cytometry. Lower left quadrants, viable cells. Lower right quadrants, early apoptotic 
cells (Annexin V+, PI -). Upper right quadrants, nonviable, late apoptotic/necrotic cells 
(Annexin V+ and PI +). The numerical results represent the mean of triplicate plates, 
and a representative experiment is shown. (Panel C), Western blot analysis. MOLM13 
and MV4-11 cells were cultured with MS-275 (0.5 or 1μM). After 48 hrs, cells were 
harvested and subjected to Western blot analysis. The membranes were sequentially 
probed with anti-Mcl-1, -Bcl-2, -Bcl-xL, -cleaved caspase 3 and 9, -cleaved PARP, and 
-α-tubulin antibodies. 
Fig. 2. Effect of MS-275 on FLT3 and its downstream signals. MV4-11 (Panel A) 
and MOLM13 (Panel B) cells were cultured with various concentrations of MS-275 
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(0.5-2 μM). After 24 hrs, cells were harvested and the phosphorylated forms, as well as 
total amount of FLT3, Akt, ERK, and STAT5 expressing populations were measured by 
flow cytometry. The figure is representative of three similar experiments. 
Fig. 3. (Panel A), MS-275 induces acetylation of HSP90 in leukemia cells. MV4-11 
and MOLM13 cells were cultured with MS-275 (1μM). After 24 hrs, cells were 
harvested and percent of cells expressing the acetylated versus total HSP90 were 
analyzed by flow cytometry. Lower right quadrants (acetylated lysine -, HSP90 +). 
Upper right quadrants, (acetylated lysine +, HSP90 +). (Panel B), MS-275 induces 
ubiquitination of FLT3 in leukemia cells. MV4-11 and MOLM13 cells were cultured 
with MS-275 (1μM). After 24 hrs, cells were harvested and percent of cells expressing 
the ubiquitinated FLT3 versus total FLT3 were analyzed by flow cytometry. Upper left 
quadrants (FLT3 +, ubiquitin -). Upper right quadrants (FLT3 +, ubiquitin +). (Panel C, 
D), MV4-11 and MOLM13 cells were cultured with MS-275 (1μM). After 24 hrs, cells 
were harvested and lysates were prepared. The lysates were immunoprecipitated with 
anti-HSP90 (Panel C) or -FLT3 (Panel D) antibody. The precipitated samples were 
subjected to Western blot analysis and the membranes were sequentially probed with the 
indicated antibodies. Immunoprecipitation. (Panel E), PS-341 blocks 
MS-275-mediated downregulation of FLT3. MV4-11 and freshly-isolated leukemia 
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cells (#1 and #2 in Table 2) were pre-incubated with either proteasome inhibitor 
PS-341(1nM) or control diluent. After 1hr, cells were exposed to either MS-275 (1μM) 
or control diluent for 24hrs. Cells were harvested and the percent of FLT3 expressing 
population was measured by flow cytometry. Results represent one of the experiments 
performed independently three times.  
Fig. 4. AZD6244 enhanced the action of MS-275 in leukemia cells. (Panel A) 
Analysis of p-ERK by FACS. MV4-11 and MOLM13 cells were cultured with either 
MS-275 (0.5 μM) or control diluent. After 24 hours, cells were exposed to either 
AZD6244 (0.25 μM) or control diluent for 15 minutes. Cells were harvested, incubated 
with anti-p-ERK antibody for 30 minutes at room temperature, and analyzed by flow 
cytometry. Results are representative of two experiments performed in duplicate plates. 
p-ERK-positive population was quantified using the CellQuest software package. 
(Panel B) MTT assay. MV4-11 and MOLM13 cells were cultured in the presence of 
either MS-275 (0.1–1 μM) and/or AZD6244 (0.1–1 μM). After 2 days, cell proliferation 
was measured by MTT assay, and concentration of each compound that induced 25, 50, 
or 75 % growth inhibition (IC25, IC50, IC75) was determined (data not shown). The 
combination index (CI) of MS-275 and AZD6244 was calculated using the median 
effect method. CI values less than 1 indicate synergy, a CI = 1 indicates an additive 
Nishioka, et al. 
 29
effect, and a CI greater than 1 indicates antagonism between the two agents. (Panel C) 
Cell cycle analysis. MV4-11 and MOLM13 cells were cultured with either MS-275 
(0.25 or 0.5 μM) and/or AZD6244 (0.25 μM). After 2 days, the cell cycle distribution of 
these cells was analyzed. The statistical significance of difference between populations 
in either sub-G1 or S phase of cell cycle induced by either MS-275 and/or AZD6244 
was determined by one-way analysis of variance (ANOVA) followed by Boneferroni’s 
multiple comparison tests. Results represent the mean ± SD of 3 experiments performed 
in triplicate; *, p< 0.01, with respect to control. (Panel D), Annexin V staining. 
MV4-11 and MOLM13 cells were cultured with either MS-275 (0.25 or 0.5 μM) and/or 
AZD6244 (0.25 μM). After 2 days, cells were stained with annexin V/propidium iodide, 
and analyzed by flow cytometry. The statistical significance of difference between 
annexin V positive populations produced by MS-275 and/or AZD6244 was determined 
by ANOVA followed by Boneferroni’s multiple comparison tests. Results represent the 
mean ± SD of 3 experiments performed in triplicate; *, p< 0.01, with respect to control. 
 
 
Table 1. Inhibition of the proliferation of leukemia cells by MS-275 
Cell Line Gene Alterations (μM)*   
Eosinophilic leukemia 
 EOL-1 FIP1L1/PDGFRα 0.74 
Biphenotypic leukemia  
 MV4-11 FLT3-ITD 0.74 
 MOLM13 FLT3-ITD 0.67  
Myeloid leukemia 
 Kasumi-1 c-KIT (Asn822Lys) 0.70 
 U937  4.6 
 THP-1  2.0 
 PL21  1.3       
 Kcl-22 BCR/ABL not achieved 
 K562 BCR/ABL 3.4 
 KU812 BCR/ABL 1.7 
Lymphoblastic leukemia 
 PALL-2 BCR/ABL 0.40         
*Concentration of MS-275 that induced 50 % growth inhibition (IC50)  
was calculated from dose-response curves. 
 
Table 2. Patient Clinical Characteristics 
 
Pt. # Age/Sex FAB WBC 
x106/L 
% Blast FLT3 
mutation
Previous 
treatment 
IC50  
(μM) 
1 61/M M1 200,000 99% ITD No 0.3 
2 55/F M1 188,400 99% ITD No 0.1 
The freshly isolated leukemia cells were cultured in the presence of various 
concentrations of MS-275 (0.01-1μM). After 2 days, the proliferation of cells was 
measured by 3[H]-thymidine-uptake. The concentration of MS-275 that induced 50 % 
growth inhibition (IC50) was calculated from the dose-response curves. 
Pt, patient; M, male; F, female; FAB, French-Amercan-British (leukaemia 
classification); ITD, internal tandem duplication; WBC, white blood cells. 
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